{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:43:01Z","timestamp":1789587781164,"version":"build-2803163510"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Melasma is a common pigmentary condition that affects the patients' quality of life and all the prescribed treatment options till now are not satisfactory, especially in dark-skinned patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To evaluate the efficacy and safety of systemic metformin (1,000 mg and 500 mg) combined with trichloroacetic acid (TCA) peeling versus TCA alone in the treatment of melasma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS AND METHODS<\/jats:title>\n            <jats:p>The study included 60 melasma patients divided into 3 groups: Group A received systemic metformin (1000 mg\/d), Group B received systemic metformin (500 mg\/d) and Group C received placebo. The 3 treatment groups were treated by TCA 25% over the whole face bimonthly for a total of 6 sessions. Melasma area and severity index (MASI), and Melasma impact Quality of life Scale (MELASQOL) were used to assess the outcome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>There was a statistically significant decrease in the MASI, and the MELASQOL in the 3 studied groups after treatment with significantly better improvement in Group (A) than Group (C) (<jats:italic toggle=\"yes\">p<\/jats:italic> = .045).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Systemic metformin is a safe and promising therapeutic option for treating melasma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000004092","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T14:02:19Z","timestamp":1709128939000},"page":"366-371","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Does Systemic Metformin Have a Role in Treating Melasma?"],"prefix":"10.1097","volume":"50","author":[{"given":"Sahar A.","family":"Ismail","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada A.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima N.","family":"Mohamedeen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Resident in Assiut Dermatology Clinic, Assuit, Egypt;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehab S.A.","family":"Sotohy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, Assiut University, Assuit, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0818-6407","authenticated-orcid":false,"given":"Radwa M.","family":"Bakr","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/09546634.2018.1524821","article-title":"Platelet-rich plasma is a useful therapeutic option in melasma","volume":"30","author":"Hofny","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/DSS.0000000000001964","article-title":"Comparative efficacy of a 35% glycolic acid peel alone or in combination with a 10% and 20% trichloroacetic acid spot peel for melasma: a randomized control trial","volume":"45","author":"Garg","year":"2019","journal-title":"Dermatol Surg"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3390\/ijms17060824","article-title":"Heterogeneous pathology of melasma and its clinical implications","volume":"17","author":"Kwon","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/ijd.13578","article-title":"Melasma: systematic review of the systemic treatments","volume":"56","author":"Zhou","year":"2017","journal-title":"Int J Dermatol"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jaad.2011.06.001","article-title":"Melasma: a comprehensive update: part II","volume":"65","author":"Sheth","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/jamafacial.2016.1666","article-title":"Universal trichloroacetic acid peel technique for light and dark skin","volume":"19","author":"Fanous","year":"2017","journal-title":"JAMA Facial Plast Surg"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/DSS.0000000000000065","article-title":"Q-switched Nd: YAG laser versus trichloroacetic acid peeling in the treatment of melasma among Egyptian patients","volume":"40","author":"Moubasher","year":"2014","journal-title":"Dermatol Surg"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0253-7613.174388","article-title":"Metformin\u2014for the dermatologist","volume":"48","author":"Bubna","year":"2016","journal-title":"Indian J Pharmacol"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1038\/jid.2014.202","article-title":"Inhibition of melanogenesis by the antidiabetic metformin","volume":"134","author":"Lehraiki","year":"2014","journal-title":"J Invest Dermatol"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.1994.01690060057005","article-title":"Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial","volume":"130","author":"Kimbrough-Green","year":"1994","journal-title":"Arch Dermatol"},{"key":"R11-20250731","first-page":"121","article-title":"Reliability and validity of the Arabic version of the Melasma Quality of Life questionnaire:(MELASQoL-A) study","volume":"2","author":"Abou-Taleb","year":"2014","journal-title":"Clin Dermatol"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1097\/DSS.0000000000002964","article-title":"Modified Jessner\u2019s solution combined with trichloroacetic acid 20% versus glycolic acid 70% combined with trichloroacetic acid 20% in the treatment of melasma","volume":"47","author":"Abdel-Majid","year":"2021","journal-title":"Dermatol Surg"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/jocd.13145","article-title":"Topical metformin in the treatment of melasma: a preliminary clinical trial","volume":"19","author":"Banavase Channakeshavaiah","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/jpri\/2019\/v30i430276","article-title":"Comparing the efficacy of topical metformin and placebo in the treatment of melasma: a randomized, double-blind, clinical trial","volume":"30","author":"Ali Mapar","year":"2019","journal-title":"J Pharm Res Int"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1111\/ajd.12474","article-title":"Oral tranexamic acid lightens refractory melasma","volume":"58","author":"Tan","year":"2017","journal-title":"Australas J Dermatol"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jocd.12291","article-title":"Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a short-term follow-up","volume":"16","author":"Lajevardi","year":"2017","journal-title":"J Cosmet Dermatol"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaad.2017.09.053","article-title":"Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma","volume":"78","author":"Del Rosario","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R18-20250731","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/ijd.12999","article-title":"An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightning agent in Filipino women","volume":"55","author":"Handog","year":"2016","journal-title":"Int J Dermatol"},{"key":"R20-20250731","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/CCID.S242180","article-title":"A treatment combination of peels, oral antioxidants, and topical therapy for refractory melasma: a report of 4 cases","volume":"13","author":"Piquero-Casals","year":"2020","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R21-20250731","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/14764170902842549","article-title":"Melasma: treatment evaluation","volume":"11","author":"Salem","year":"2009","journal-title":"J Cosmet Laser Ther"},{"key":"R22-20250731","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4103\/0378-6323.66602","article-title":"Comparative study of trichloroacetic acid versus glycolic acid chemical peels in the treatment of melasma","volume":"76","author":"Kumari","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R23-20250731","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijwd.2017.01.004","article-title":"A review of laser and light therapy in melasma","volume":"3","author":"Trivedi","year":"2017","journal-title":"Int J Women's Dermatol"},{"key":"R25-20250731","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.3889\/oamjms.2019.407","article-title":"Is there a correlation between severity of melasma and quality of life?","volume":"7","author":"Jusuf","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"R26-20250731","doi-asserted-by":"crossref","first-page":"519","DOI":"10.4103\/0019-5154.164415","article-title":"Clinico-epidemiological study and quality of life assessment in melasma","volume":"60","author":"Yalamanchili","year":"2015","journal-title":"Indian J Dermatol"},{"key":"R27-20250731","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/09546630802287553","article-title":"Validation of a melasma quality of life questionnaire for the Turkish language: the MelasQoL-TR study","volume":"20","author":"Dogramaci","year":"2009","journal-title":"J Dermatolog Treat"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:02:13Z","timestamp":1753999333000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000004092","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]}}}